HR Execs on the Move

BioDelivery Sciences International

www.bdsi.com

 
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.bdsi.com
  • 4131 Parklake Avenue Suite 225
    Raleigh, NC USA 27612
  • Phone: 919.582.9050

Executives

Name Title Contact Details
John Golubieski
Chief Financial Officer Profile
Terry Coelho
Executive Vice President and Chief Financial Officer Profile

Similar Companies

Acumen Pharmaceuticals

Acumen Pharmaceuticals is a Livermore, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ETHEX

ETHEX Corp. is a Bridgeton, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tweed

Tweed and our sister company Tweed Farms are wholly owned subsidiaries of Tweed Marijuana Inc., traded on the TSX Venture Exchange as TWD. We are a Canadian company licensed under the Marihuana for Medical Purposes Regulations. We strive to supply a wide selection of marijuana, as diverse as the patients who trust us with their patronage.

Sanofi

3129 Sanofi SA is a French multinational healthcare company headquartered in Paris, France.

RedPath Integrated Pathology, Inc

RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory. The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers.